Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Pivotal Bioventure
BioCentury | Mar 27, 2025
Emerging Company Profile
Heranova: Detecting endometriosis in the blood like it’s cancer
The Massachusetts-based company launched a microRNA-based liquid biopsy test for endometriosis, with an eye toward disease monitoring and drug development
BioCentury | Jan 6, 2024
Finance
Jan. 5 Quick Takes: Metagenomi, ArriVent file for IPO
Plus: Immunic eyes $240M private placement and updates from Applied Therapeutics and Novartis
BioCentury | Dec 19, 2023
Deals
Dec. 18 Quick Takes: Illumina to divest Grail
Plus: Pivotal closes $389M Partners Fund II and updates from Novo Nordisk Foundation, Mirum, Santhera, Arcutis and Checkpoint
BioCentury | Sep 28, 2023
Deals
Sept. 27 Quick Takes: Roche and Ionis taking another approach to Huntington disease
Plus: Venture financings for Avalyn, Sitryx and Singaporean newco Automera and updates from Biohaven, Ginkgo, Pfizer, Gilead and Gracell
BioCentury | Apr 27, 2023
Emerging Company Profile
Evommune: advancing ex-Dermira assets, screening for new programs using human tissue
Backed with $145M since 2020, the biotech has a Phase IIa molecule for atopic dermatitis, plus at least two preclinical programs
BioCentury | Dec 14, 2022
Emerging Company Profile
Lucy: mitochondrial solutions to CNS diseases
Company’s first indications are Parkinson’s disease, Rett syndrome
BioCentury | Nov 7, 2022
Finance
With Phase III looming, Enavate leads $118M round for Moulder’s Zenas
Patient Square-backed vehicle leads round, with trial in IgG4-related diseases imminent for lead program
BioCentury | Oct 18, 2022
Deals
Oct. 17 Quick Takes: Gilead, MacroGenics in deal for bispecific
Biogen’s ALS candidate delayed, plus updates from Oculis, Treeline, Minerva, Acrivon and more
BioCentury | Feb 24, 2022
Finance
Fresh off Amgen deal, Plexium raises $102M for degrader platform
BVF Partners, TCG Crossover co-lead funding to advance Plexium’s cell- and DEL-based degrader discovery tech
BioCentury | Feb 11, 2022
Deals
Feb. 10 Quick Takes: RA, Adjuvant ready Curevo to take on Shingrix with $60M A round
Seagen slides on guidance, and updates from Arkuda, Altesa, Aeglea, Congruence, 1859 and more
Items per page:
1 - 10 of 62